Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03906071
Title	Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE)
Acronym	SAPPHIRE
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Mirati Therapeutics Inc.
Indications	lung non-squamous non-small cell carcinoma
Therapies	Docetaxel Nivolumab + Sitravatinib
Age Groups:	adult \| senior
Covered Countries	USA \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL